Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κb) Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023

NF-kb (Nuclear factor kappa light chain enhancer of activated B cells) is a family of transcription factors. These are highly conserved factors that control the transcription of DNA, cytokine production, apoptosis, cell growth, and cell survival. It plays a crucial role in regulating responses to infection. It has a role in cellular responses to stimuli such as stress, UV radiation, heavy metals, oxidized LDL, and bacterial and viral antigens. Proper regulation of NF-κB is crucial for the normal functioning of the organs and functions in the body. Incorrect regulation has been linked to various diseases like cancer, inflammatory and autoimmune diseases, septic shock, viral diseases, and improper immune development. Therefore, inhibiting it might be an approach to treating various conditions associated with the pathway. Research is being conducted globally to discover new and novel molecules for anti-IL-23 agents. The development and launch of new products will thus increase the revenue of the market in the forecasted years. According to the Department of Health and Human Services, in 2022, the USA had approximately 9.9 per 100,000 people suffering from Amyotrophic Lateral Sclerosis (AML). According to a research study, the incidence of AML in Europe is about 2.2 per 100,000 people in 2022. Therefore, there is an opportunity for the market players globally.

A number of these inhibitors are in the market, while many are in ongoing clinical trials. 66 companies have various products in their pipelines, with 51 products in various stages of clinical trials. 7 products are in Phase 4, 12 in Phase 3, 24 in Phase 2, and 8 in Phase 1 of the clinical trials.

Key Developments of NF-κB Inhibitors

• In April 2020, FDA approved Bafiertam (monomethyl fumarate) for the treatment of adults with relapsing forms of Multiple Sclerosis (MS).

Approved Molecules Of Nf-Κb Inhibitors

• Kremezin (Ast-120)
• Fumaderm (Dimethyl Fumarate)
• Careram (Iguratimod)
• Erdotin (Erdosteine)
• Kanglaite Injection (Klti)
• Skilarence (Dimethyl Fumarate)
• Bafiertam (Monomethyl Fumarate)

Drugs In The Pipeline Of Nf-Κb Inhibitors

• Bardoxolone Methyl (Rta 402)
• Vamorolone (Vbp15)
• Hocena (Antroquinonol)
• Imr-261
• Saccovid (Efprezimod Alfa)
• Triolex (Ne3107)
• Edasalonexent (Cat-1004)
• Kappaproct (Cobitolimod)
• Dimethylamino Micheliolide (Act001)
• Ornithine Phenylacetate Oral (Mnk-6106)
• Hmpl-004
• Dexanabinol (Ets2101)
• Recoflavone (Da-6034)
• Cbl137 Iv
• Sar 113945
• Tarenflurbil (Mk-50)
• Ot-551
• Trunoc (Tarenflurbil)
• Dendrimer N-Acetyl-Cysteine (Op-101)
• Dimethyl Fumarate-Controlled Release (Fp 187)
• Niclosamide (Fw-1022)
• Zenuzolac (Vgx-1027)
• Apx3330
• Kominox (Sodium Metaarsenite)
• Lipocurc (Liposomal Curcumin)
• Sdp-4
• Curcumin/ Doxorubicin (Imx-110)
• Luxeptinib (Cg-806)
• Oleandrin (Pbi-05204)
• Ornithine Phenylacetate Iv (Mnk-6105)
• Quinacrine (Cbl0102)
• Amg0103
• Cbl0137 Ia
• Cxa-10 Iv
• Curcusome-Ra
• Kanglaite Gelcap (Kltc)
• Nf-Kappa-B Decoy Oligonucleotide Topical (Amg0101 Topical)
• Rhn001
• Sr13668
• Apocynin/Paeonol (Akl-4)
• Hypochlorous Acid (Pr022)
• Meclocycline (Snx-1012)
• Misetionamide (Gp-2250)
• Resveratrol (Db02709)

Clinical Activity and Developments of NF-κB Inhibitors

As of June 2023, 66 companies have approximately 51 products for 243 diseases. For these diseases, 52 trials are being conducted by players globally. For instance,

• Sunnybrook Health Sciences Centre is conducting a Phase 2 clinical trial to evaluate the safety of Withania Somnifera- NF-?b Inhibitor in patients with Amyotrophic Lateral Sclerosis that was expected t complete by September 2022.
• Guang’anmen Hospital of China Academy of Chinese Medical Sciences is conducting a Phase 4 clinical trial to evaluate the efficacy and safety of Kanglaite injection (KLTi) for advanced non-small cell lung cancer (NSCLC) that is expected to complete by May 2022.
• Kyowa Kirin Co., Ltd is conducting a Phase 3 clinical trial to study the efficacy of Bardoxolone Methyl in patients with Diabetic Kidney Disease.